PT  - JOURNAL ARTICLE
AU  - Rulli, Maria Cristina
AU  - D’Odorico, Paolo
AU  - Galli, Nikolas
AU  - Hayman, David T.S.
TI  - Land Use Change and Coronavirus Emergence Risk
AID  - 10.1101/2020.07.31.20166090
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.31.20166090
4099  - http://medrxiv.org/content/early/2020/08/04/2020.07.31.20166090.short
4100  - http://medrxiv.org/content/early/2020/08/04/2020.07.31.20166090.full
AB  - Coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) causing coronaviruses are mostly discovered in Asian horseshoe bats. It is still unclear how ongoing land use changes may facilitate SARS-related coronavirus transmission to humans. Here we use a multivariate hotspot analysis of high-resolution land-use data to show that regions of China populated by horseshoe bats are hotspots of forest fragmentation, livestock and human density. We also identify areas susceptible to new hotspot emergence in response to moderate expansion of urbanization, livestock production, or forest disturbance, thereby highlighting regions vulnerable to SARS-CoV spillover under future land-use change. In China population growth and increasing meat consumption associated with urbanization and economic development have expanded the footprint of agriculture, leading to human encroachment in wildlife habitat and increased livestock density in areas adjacent to fragmented forests. The reduced distance between horseshoe-bats and humans elevates the risk for SARS-related coronavirus transmission to humans.Sentence summarizing manuscript Wildlife reservoirs for SARS-coronavirus-2 live in global hotspots of forest fragmentation, livestock, and human density in ChinaCompeting Interest StatementThe authors have declared no competing interest.Funding StatementM.C.R and N.G. are supported by Cariplo Foundation (SusFeed project 0737 CUPD49H170000300007). D.T.S.H. is supported by Rutherford Discovery Fellowship RDF MAU1701.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This has no patient data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available